Launch of Travoprost ophthalmic solution USP, 0.004 per cent adds to the company's portfolio of prescription ophthalmic products, said Glenmark Pharmaceuticals Senior Vice President, Jim Brown. Image ...

Results from the NCX 470 Phase 3b Whistler Mechanism of Action trial expected in Q1 2025 ...

Press Release Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream First ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of travoprost ophthalmic solution USP, 0.004% (ionic buffered solution). Glenmark’s travoprost ophthalmic solution USP, 0.004% is ...

The Denali trial is evaluating the intraocular pressure (IOP) lowering efficacy of once-daily dosed NCX 470 ophthalmic solution 0.1% ... nitric oxide (NO)-donating bimatoprost eye drop that ...

today announced the first commercial sale of ZERVIATE® (cetirizine ophthalmic solution), 0.24% in China by its exclusive Chinese partner Ocumension Therapeutics. ZERVIATE is indicated for ocular ...

underscoring its role as a complementary tool rather than a standalone diagnostic solution. The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and ...

The ophthalmic nerve is the first branch of the trigeminal nerve, which is also known as the fifth cranial nerve. The ophthalmic nerve supplies sensory innervation to the structures of the eye, ...

The ophthalmic pathology fellowship program will last for one or two years, and involves microscopic and molecular studies of tumors and other diseases of the eye and orbit. The broad goal is to ...